Cost of medical injury in New Zealand: A retrospective cohort study

Brown, Paul; McArthur, Colin; Newby, Lynette; Lay‐Yee, Roy; Davis, Peter; Briant, Robin

doi:10.1258/135581902320176449

Cited by 31 publications

(31 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The economical impact of adverse events has been gaining particular attention in the last years [26,27]. The report of the Institute of Medicine estimates that, in the United States, the total national costs associated with adverse events represent approximately 4% to 6% of national health expenditures [9].…”

Section: Discussionmentioning

confidence: 99%

Estimating the incidence of adverse events in Portuguese hospitals: a contribution to improving quality and patient safety

Sousa

Uva

Serranheira

et al. 2014

BMC Health Serv Res

View full text Add to dashboard Cite

BackgroundSeveral review studies have shown that 3.4% to 16.6% of patients in acute care hospitals experience one or more adverse events. Adverse events (AEs) in hospitals constitute a significant problem with serious consequences and a challenge for public health. The occurrence of AEs in Portuguese hospitals has not yet been systematically studied. The main purpose of this study is to estimate the incidence, impact and preventability of adverse events in Portuguese hospitals. It is also our aim to examine the feasibility of applying to Portuguese acute hospitals the methodology of detecting AEs through record review, previously used in other countries.MethodsThis work is based on a retrospective cohort study and was carried out at three acute care hospitals in the Administrative Region of Lisbon. The identification of AEs and their impact was done using a two-stage structured retrospective medical records review based on the use of 18 screening criteria. A random sample of 1,669 medical records (representative of 47,783 hospital admissions) for the year 2009 was analyzed.ResultsThe main results found in this study were an incidence rate of 11.1% AEs, of which around 53.2% were considered preventable. The majority of AEs were associated with surgical procedures (27%), drug errors (18.3%) and hospital acquired infections (12.2%). Most AEs (61%) resulted in minimal or no physical impairment or disability, and 10.8% were associated with death. In 58.6% of the AEs’ cases, the length of stay was prolonged on average 10.7 days. Additional direct costs amounted to €470,380.00.ConclusionThe magnitude of these results was critical, reinforcing the need of more detailed studies in this area. The knowledge of the incidence and nature of AEs that occur in hospitals should be seen as a first step towards the improvement of quality and safety in health care.

show abstract

Section: Discussionmentioning

confidence: 99%

Estimating the incidence of adverse events in Portuguese hospitals: a contribution to improving quality and patient safety

Sousa

Uva

Serranheira

et al. 2014

BMC Health Serv Res

View full text Add to dashboard Cite

show abstract

“…AEs are widely agreed to be a serious problem with severe consequences on the patient safety [3] and they pose an economic burden on health care system as well, since high rates of AEs are associated with the increase in health care costs for patient management, mainly due to prolonged hospital stay and the use of additional treatments [4,5].…”

Section: Introductionmentioning

confidence: 99%

Adverse events in hospitalized paediatric patients: a systematic review and a meta‐regression analysis

Berchialla

Scaioli²,

Passi³

et al. 2014

Evaluation Clinical Practice

View full text Add to dashboard Cite

Objectives. To gain insight into the incidence of pediatric adverse events (AEs); to assess if there are significant differences among study results and to what extent methodological issues can explain them.Methods. From November 2012 to January 2013, systematic literature searches were conducted on PubMed, Scopus and the Cochrane Library. We selected studies from 1970 onwards that evaluated the incidence of AEs in hospitalized pediatric patients and included a minimum of 1000 patient records with the same definition of AE. Studies that reported only specific AEs or only a specific ward were not considered. Data were extracted on the method of data collection, study design, type of hospital, and the timing of the AE in relation to its discovery and the index admission (time frame). AE incidence and preventability were considered.Results. The pooled incidence of AEs was 2.0% (95%CI: 1.3%-3.0%). Five methodological differences among studies were taken into account. Only the time frame of detected events had a statistically significant effect on the incidence of AEs (p<0.0001). The pooled incidence of preventable AEs was 46.2% (95% CI: 35.3%-57.5%) with a high variability among studies. Conclusions.Our meta-analysis confirms that AEs are a major public health issue. Although studies use the same definition of adverse event, the reported incidence of AEs and preventable AEs varied considerably. To direct prevention efforts properly, studies methodologically more homogeneous and more detailed about the standard of health care provided and the health system organization, are needed.3

show abstract

“…The incidence, costs and consequences of medication errors are well described in the literature. [1][2][3] As a result of this, there has been an increasing focus on the safe and quality use of medicines on an international level. In New Zealand this has been reflected in the creation of several national initiatives and groups [4,5] (see the homepages of the Safe Medication Management Programme, www.safemedication.org.nz/, and The Quality and Safe Use of Medicines Group, www.safeuseofmedicines.co.nz/).…”

Section: Introductionmentioning

confidence: 99%

Key performance indicators for clinical pharmacy services in New Zealand public hospitals: stakeholder perspectives

Harrison

2010

Journal of Pharmaceutical Health Services Research

View full text Add to dashboard Cite

Objective To identify a set of measurable key performance indicators (KPIs) demonstrating hospital clinical pharmacy's contribution to patient care that can be used for benchmarking in the New Zealand setting. Methods Data sources were key stakeholders from public hospitals in each of the 21 District Health Boards in New Zealand. Surveys with selected KPIs thought to represent clinical pharmacy's contribution to patient care were sent to the Chief Pharmacist, Chief Medical Officer, Director of Nursing, senior management team and Quality and Risk Manager of each District Health Board, who were asked to rate each KPI based on relevance to clinical pharmacy's contribution to patient care and ease of measurement in their organisation. Mailed survey data were ranked and analysed using Microsoft Excel and SPSS. Key findings The response rate was 43%. The top two ranked KPIs were concerning chart review and medication reconciliation. Only three of 52 KPIs were rated ‘easily’ measurable. No statistically significant differences were seen between professional groups or hospital sizes. Conclusions The top ranked KPIs reflected the pharmacist's central role in improving the individual patient's medicines use. Measurability appeared to be a major issue due to resource constraints. This study has provided the platform for future nationwide hospital clinical pharmacy KPIs.

show abstract

Cost of medical injury in New Zealand: A retrospective cohort study

Abstract: Adverse events lead to a significant use of health care resources in New Zealand. These findings suggest that substantial resources could be saved by eliminating preventable adverse events.

Cited by 31 publications

References 14 publications

Estimating the incidence of adverse events in Portuguese hospitals: a contribution to improving quality and patient safety

Estimating the incidence of adverse events in Portuguese hospitals: a contribution to improving quality and patient safety

Adverse events in hospitalized paediatric patients: a systematic review and a meta‐regression analysis

Key performance indicators for clinical pharmacy services in New Zealand public hospitals: stakeholder perspectives

Contact Info

Product

Resources

About